Related references
Note: Only part of the references are listed.Mechanistic and Pharmacological Characterization of PF-04457845: A Highly Potent and Selective Fatty Acid Amide Hydrolase Inhibitor That Reduces Inflammatory and Noninflammatory Pain
Kay Ahn et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor
Douglas S. Johnson et al.
ACS MEDICINAL CHEMISTRY LETTERS (2011)
Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders
Kay Ahn et al.
EXPERT OPINION ON DRUG DISCOVERY (2009)
Endogenous ethanolamide analysis in human plasma using HPLC tandem MS with electrospray ionization
Joe Palandra et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2009)
Enzymatic pathways that regulate endocannabinoid signaling in the nervous system
Kay Ahn et al.
CHEMICAL REVIEWS (2008)
The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1, TRPV1 and PPARγ receptors and neurotrophic factors
Barbara Costa et al.
PAIN (2008)
The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3′-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice
Roberto Russo et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Cognitive testing in early-phase clinical trials: Development of a rapid computerized test battery and application in a simulated Phase I study
Alex Collie et al.
CONTEMPORARY CLINICAL TRIALS (2007)
Assessment of anandamide's pharmacological effects in mice deficient of both fatty acid amide hydrolase and cannabinoid CB1 receptors
Laura E. Wise et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms
Leon Chang et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
Cognitive testing in early phase clinical trials: outcome according to adverse event profile in a Phase I study
Alex Collie et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2006)
Biochemical mechanisms of drug action: what does it take for success?
DC Swinney
NATURE REVIEWS DRUG DISCOVERY (2004)
Characterization of the sleep-wake patterns in mice lacking fatty acid amide hydrolase
S Huitron-Resendiz et al.
SLEEP (2004)
Antibody pharmacokinetics and pharmacodynamics
ED Lobo et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: Evidence for an unprecedented combination of potency and selectivity
AH Lichtman et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia
AH Lichtman et al.
PAIN (2004)
Modulation of anxiety through blockade of anandamide hydrolysis
S Kathuria et al.
NATURE MEDICINE (2003)
Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications
T Bisogno et al.
CURRENT PHARMACEUTICAL DESIGN (2002)
Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase
BF Cravatt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Exceptionally potent inhibitors of fatty acid amide hydrolase: The enzyme responsible for degradation of endogenous oleamide and anandamide
DL Boger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
